Savara (NASDAQ:SVRA) Sees Unusually-High Trading Volume After Insider Buying Activity

Savara Inc (NASDAQ:SVRA) saw unusually-high trading volume on Wednesday following insider buying activity. Approximately 5,254,916 shares were traded during trading, an increase of 318% from the previous session’s volume of 1,257,429 shares.The stock last traded at $3.15 and had previously closed at $2.94.

Specifically, Director Joseph S. Mccracken bought 20,000 shares of Savara stock in a transaction dated Tuesday, November 19th. The shares were bought at an average cost of $2.95 per share, with a total value of $59,000.00. Following the acquisition, the director now owns 210,837 shares in the company, valued at $621,969.15. This trade represents a 10.48 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Analysts Set New Price Targets

A number of research firms have issued reports on SVRA. JMP Securities reiterated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Evercore ISI reissued an “in-line” rating and issued a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, HC Wainwright decreased their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Price Performance

The firm has a 50 day moving average price of $3.82 and a two-hundred day moving average price of $4.16. The company has a market cap of $538.89 million, a P/E ratio of -7.23 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, analysts predict that Savara Inc will post -0.45 EPS for the current fiscal year.

Hedge Funds Weigh In On Savara

Institutional investors and hedge funds have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co bought a new stake in shares of Savara in the 1st quarter worth approximately $35,000. Choreo LLC bought a new stake in Savara during the second quarter valued at about $59,000. DRW Securities LLC bought a new stake in Savara during the second quarter valued at about $62,000. Principal Financial Group Inc. lifted its position in shares of Savara by 64.4% in the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares in the last quarter. Finally, Profund Advisors LLC purchased a new stake in shares of Savara in the second quarter worth about $105,000. 87.93% of the stock is currently owned by institutional investors.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.